0001855763-24-000005.txt : 20240510
0001855763-24-000005.hdr.sgml : 20240510
20240510164446
ACCESSION NUMBER: 0001855763-24-000005
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240426
FILED AS OF DATE: 20240510
DATE AS OF CHANGE: 20240510
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BUNKA CHRISTOPHER
CENTRAL INDEX KEY: 0001103780
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39874
FILM NUMBER: 24935660
MAIL ADDRESS:
STREET 1: 1924 BIRKDALE AVE
CITY: KELOWNA
STATE: A1
ZIP: V1P1R7
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Lexaria Bioscience Corp.
CENTRAL INDEX KEY: 0001348362
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 202000871
STATE OF INCORPORATION: NV
FISCAL YEAR END: 0831
BUSINESS ADDRESS:
STREET 1: 100 - 740 MCCURDY ROAD
CITY: KELOWNA
STATE: A1
ZIP: V1X 2P7
BUSINESS PHONE: 250-765-6424
MAIL ADDRESS:
STREET 1: 100 - 740 MCCURDY ROAD
CITY: KELOWNA
STATE: A1
ZIP: V1X 2P7
FORMER COMPANY:
FORMER CONFORMED NAME: LEXARIA CORP.
DATE OF NAME CHANGE: 20080229
FORMER COMPANY:
FORMER CONFORMED NAME: Lexaria Corp.
DATE OF NAME CHANGE: 20051229
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0508
4
2024-04-26
0
0001348362
Lexaria Bioscience Corp.
LEXX
0001103780
BUNKA CHRISTOPHER
1924 BIRKDALE AVE
KELOWNA
A1
V1P1R7
BRITISH COLUMBIA, CANADA
1
1
0
0
Chief Executive Officer
0
common shares
273543
D
common shares
254412
I
Private Holding Company
Warrants
10.5
2020-05-06
2025-05-06
Common Shares
6667
6667
I
Private Holding Company
Stock Options
3
2021-04-26
2026-04-26
Common Shares
26000
32667
D
Stock Options
3
2021-06-08
2026-06-08
Common Shares
23334
56001
D
Stock Options
3
2021-09-01
2026-09-01
Common Shares
15000
71001
D
Stock Options
2.91
2022-08-29
2027-08-29
Common Shares
30000
101001
D
Stock Options
1.15
2023-10-26
2028-10-26
Common Shares
30000
131001
D
Stock Options
2.36
2024-04-26
4
A
0
49500
0
A
2024-04-26
2029-04-26
Common Shares
49500
180501
D
Repriced from $5.83 pursuant to shareholder approval received on May 9, 2023
Repriced from $7.08 pursuant to shareholder approval received on May 9, 2023
Repriced from $6.23 pursuant to shareholder approval received on May 9, 2023
/Chris Bunka/
2024-05-10